GNPX · Genprex Inc
United States · RS rating 21 · As of 2026-10-14
| Price | 2.33 USD |
|---|---|
| 1-day change | -7.2% |
| RS rating (overall / 1M / 3M / 12M) | 21 / 6 / 2 / 7 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 22 / 38 / 33 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +33.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +94.5% |
| Market cap (USD) | $9.2M |